Tumor mutation burden (TMB), defined as the total number of coding mutations in the tumor genome, has emerged as a promising predictive biomarker of response to anti-PD-1/PD-L1 agents in several prospective trials, which have included multiple tumor types [127–129]. The gene discussed is CD274; the disease is neoplasm.